Physician profile
Blair Hoffman
NPI 1407227606
$2,550.34
in general payments reported to CMS, 2019-2025
41 companies · $604 in 2025
The $604 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $495 · 2023: $702 · 2024: $536 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $340.77 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $304.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Ucb, INC. | $225.24 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $158.29 | 2021-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $137.78 | 2023-2025 | |
| Abbvie INC. | $128.79 | 2022-2024 | |
| Janssen Biotech, INC. | $124.87 | 2022-2025 | Tremfya |
| Xeris Pharmaceuticals, INC. | $90.50 | 2021-2023 | Gvoke Hypopen |
| Argenx US, INC. | $77.30 | 2023-2025 | Vyvgart Hytrulo |
| Eisai INC. | $75.41 | 2021-2024 | |
| Dexcom, INC. | $69.55 | 2022-2024 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $67.67 | 2023-2024 | Prolastin-C Liquid, Gamunex-C |
| Pfizer INC. | $64.28 | 2023-2024 | |
| Astellas Pharma US INC | $63.18 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $48.81 | 2023-2025 | Rexulti, Nuedexta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blair Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.